210 related articles for article (PubMed ID: 27272846)
1. Thyroid Hormones and Vitamin D in Patients with Breast Cancer with Mutations in BRCA1 or BRCA2 Genes.
Kolben T; Hary T; Holdt LM; Schwarz TM; Goess C; Wuerstlein R; Gallwas J; Toth B; Weissenbacher T; Jeschke U; Harbeck N; Ditsch N
Anticancer Res; 2016 Jun; 36(6):3185-90. PubMed ID: 27272846
[TBL] [Abstract][Full Text] [Related]
2. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
3. BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis.
Zhu Y; Wu J; Zhang C; Sun S; Zhang J; Liu W; Huang J; Zhang Z
Oncotarget; 2016 Oct; 7(43):70113-70127. PubMed ID: 27659521
[TBL] [Abstract][Full Text] [Related]
4. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.
Kirova YM; Stoppa-Lyonnet D; Savignoni A; Sigal-Zafrani B; Fabre N; Fourquet A;
Eur J Cancer; 2005 Oct; 41(15):2304-11. PubMed ID: 16140006
[TBL] [Abstract][Full Text] [Related]
5. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers.
Milne RL; Osorio A; Ramón y Cajal T; Baiget M; Lasa A; Diaz-Rubio E; de la Hoya M; Caldés T; Teulé A; Lázaro C; Blanco I; Balmaña J; Sánchez-Ollé G; Vega A; Blanco A; Chirivella I; Esteban Cardeñosa E; Durán M; Velasco E; Martínez de Dueñas E; Tejada MI; Miramar MD; Calvo MT; Guillén-Ponce C; Salazar R; San Román C; Urioste M; Benítez J
Breast Cancer Res Treat; 2010 Jan; 119(1):221-32. PubMed ID: 19370414
[TBL] [Abstract][Full Text] [Related]
6. Epidemiological and clinicopathological characteristics of BRCA-positive and BRCA-negative breast cancer patients in Greece.
Triantafyllidou O; Vlachos IS; Apostolou P; Konstantopoulou I; Grivas A; Panopoulos C; Dimitrakakis C; Kassanos D; Loghis C; Bramis I; Vlahos N; Yannoukakos D; Fostira F
J BUON; 2015; 20(4):978-84. PubMed ID: 26416046
[TBL] [Abstract][Full Text] [Related]
7. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
[TBL] [Abstract][Full Text] [Related]
8. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
[TBL] [Abstract][Full Text] [Related]
9. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
Lancet; 1997 May; 349(9064):1505-10. PubMed ID: 9167459
[TBL] [Abstract][Full Text] [Related]
10. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study.
Goodwin PJ; Phillips KA; West DW; Ennis M; Hopper JL; John EM; O'Malley FP; Milne RL; Andrulis IL; Friedlander ML; Southey MC; Apicella C; Giles GG; Longacre TA
J Clin Oncol; 2012 Jan; 30(1):19-26. PubMed ID: 22147742
[TBL] [Abstract][Full Text] [Related]
12. Ionizing radiation or mitomycin-induced micronuclei in lymphocytes of BRCA1 or BRCA2 mutation carriers.
Gutiérrez-Enríquez S; Ramón Y Cajal T; Alonso C; Corral A; Carrasco P; Cornet M; Sanz J; Ribas M; Baiget M; Diez O
Breast Cancer Res Treat; 2011 Jun; 127(3):611-22. PubMed ID: 20625817
[TBL] [Abstract][Full Text] [Related]
13. The incidence of cardiomyopathy in BRCA1 and BRCA2 mutation carriers after anthracycline-based adjuvant chemotherapy.
Pearson EJ; Nair A; Daoud Y; Blum JL
Breast Cancer Res Treat; 2017 Feb; 162(1):59-67. PubMed ID: 28066861
[TBL] [Abstract][Full Text] [Related]
14. Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers.
Cullinane CA; Lubinski J; Neuhausen SL; Ghadirian P; Lynch HT; Isaacs C; Weber B; Moller P; Offit K; Kim-Sing C; Friedman E; Randall S; Pasini B; Ainsworth P; Gershoni-Baruch R; Foulkes WD; Klijn J; Tung N; Rennert G; Olopade O; Couch F; Wagner T; Olsson H; Sun P; Weitzel JN; Narod SA
Int J Cancer; 2005 Dec; 117(6):988-91. PubMed ID: 15986445
[TBL] [Abstract][Full Text] [Related]
15. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases.
Brekelmans CT; Tilanus-Linthorst MM; Seynaeve C; vd Ouweland A; Menke-Pluymers MB; Bartels CC; Kriege M; van Geel AN; Burger CW; Eggermont AM; Meijers-Heijboer H; Klijn JG
Eur J Cancer; 2007 Mar; 43(5):867-76. PubMed ID: 17307353
[TBL] [Abstract][Full Text] [Related]
16. Association of BRCA Mutation Types, Imaging Features, and Pathologic Findings in Patients With Breast Cancer With BRCA1 and BRCA2 Mutations.
Ha SM; Chae EY; Cha JH; Kim HH; Shin HJ; Choi WJ
AJR Am J Roentgenol; 2017 Oct; 209(4):920-928. PubMed ID: 28796549
[TBL] [Abstract][Full Text] [Related]
17. Mammographic density and breast cancer in women from high risk families.
Ramón Y Cajal T; Chirivella I; Miranda J; Teule A; Izquierdo Á; Balmaña J; Sánchez-Heras AB; Llort G; Fisas D; Lope V; Hernández-Agudo E; Juan-Fita MJ; Tena I; Robles L; Guillén-Ponce C; Pérez-Segura P; Luque-Molina MS; Hernando-Polo S; Salinas M; Brunet J; Salas-Trejo MD; Barnadas A; Pollán M
Breast Cancer Res; 2015 Jul; 17(1):93. PubMed ID: 26163143
[TBL] [Abstract][Full Text] [Related]
18. CASP8 D302H polymorphism delays the age of onset of breast cancer in BRCA1 and BRCA2 carriers.
Palanca Suela S; Esteban Cardeñosa E; Barragán González E; de Juan Jiménez I; Chirivella González I; Segura Huerta A; Guillén Ponce C; Martínez de Dueñas E; Montalar Salcedo J; Castel Sánchez V; Bolufer Gilabert P;
Breast Cancer Res Treat; 2010 Jan; 119(1):87-93. PubMed ID: 19214744
[TBL] [Abstract][Full Text] [Related]
19. Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations.
Kadouri L; Hubert A; Rotenberg Y; Hamburger T; Sagi M; Nechushtan C; Abeliovich D; Peretz T
J Med Genet; 2007 Jul; 44(7):467-71. PubMed ID: 17307836
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer risk in BRCA1 and BRCA2 mutation carriers and polyglutamine repeat length in the AIB1 gene.
Hughes DJ; Ginolhac SM; Coupier I; Barjhoux L; Gaborieau V; Bressac-de-Paillerets B; Chompret A; Bignon YJ; Uhrhammer N; Lasset C; Giraud S; Sobol H; Hardouin A; Berthet P; Peyrat JP; Fournier J; Nogues C; Lidereau R; Muller D; Fricker JP; Longy M; Toulas C; Guimbaud R; Yannoukakos D; Mazoyer S; Lynch HT; Lenoir GM; Goldgar DE; Stoppa-Lyonnet D; Sinilnikova OM
Int J Cancer; 2005 Nov; 117(2):230-3. PubMed ID: 15900600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
